NEW DELHI, Mar 2: Glenmark Pharmaceuticals is recalling nearly 1.5 million bottles of a generic drug intended for the treatment of attention deficit hyperactivity disorder (ADHD) in the United States, as reported by the US health regulator. Glenmark Pharmaceuticals Inc., the US branch of the Mumbai-based company, is recalling about 1,476,000 bottles of Atomoxetine Capsules […]